April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
August 2023 in “JAAD Case Reports” A woman with lupus experienced hair regrowth after treatment, but hair transplantation is not advised for her condition.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
November 2025 in “Preprints.org” The gel effectively reduced folliculitis symptoms and was safe to use.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
January 2025 in “Journal of Food Biochemistry” 2′‐Fucosyllactose reduces hair loss and promotes hair growth in mice.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.